News | February 16, 2024
Glenmark Pharma posts Q3 FY24 net loss of Rs. 331 Cr
he lower sales in the current quarter are mainly on account of a one?time impact on the company’s India business
he lower sales in the current quarter are mainly on account of a one?time impact on the company’s India business
The talk show will be held monthly via Medanta's YouTube, Facebook and LinkedIn channe
The CDCCs are strategically positioned in regions identified as high-impact areas
MASH is a chronic and progressive liver disease characterised by fat accumulation and inflammation in the liver,
The US FDA's clearance of the trial marks the first global registrational Phase III trial for olverembatinib in patients with CP-CML to be conducted.
The new tests can support clinical decision making when prescribing direct oral anticoagulants for stroke prevention
Bromfenac Ophthalmic Solution 0.075% (RLD BromSite) had estimated annual sales of USD 15 million in the U.S.
The company is committed to a new category development in areas like adult Immunization with products like Shingrix to make a positive impact to the lives of the patients in India
Launches collaborative centre for translational research in head and neck cancer
The agreement is effective from January 1, 2024 and commercialisation commenced on February 1, 2024
Subscribe To Our Newsletter & Stay Updated
